CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE...The Exclusive License Agreement • February 29th, 2024 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”) is made effective May 21, 2021 (the “First Amendment’s Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at [***] (“The Regents”), acting through The Technology Development Group of the University of California, Los Angeles (“UCLA”), located at [***], and Sana Biotechnology, Inc. (“Licensee”), a Delaware Corporation having its principal place of business at 188 E. Blaine St., Suite 400, Seattle WA 98102, and amends the license agreement with Licensee, dated March 01, 2019 with UC Agreement Control Number [***] (the “Agreement”).
Certain confidential information contained in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private...Patent License Agreement • February 29th, 2024 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 (“Amendment No. 1”), with an effective date of December 30, 2022 (“Amendment No. 1 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Rochester (“University”).
